This project is part of the EDCTP3 programme supported by the European Union
Speakers and presentations Shaping the future: advancing equitable and ethical research to meet women’s therapeutic needs Location: Kigali Convention Center, Room MH3Date & time: Tuesday, 17 June from 16:30 to 18:00 Dr Stephanie Dellicour, Principal Research Associate, Liverpool School of
Kisumu, Kenya and Geneva, Switzerland 10 July 2024. The Safety of Antimalarials in the FIrst TRimEster (SAFIRE) consortium, made up of scientific and social research experts in malaria in pregnancy, has today kicked off the preparation of a historic project: the first-ever Phase
Malaria is a dangerous disease. One that, according to the World Health Organization, resulted in 249 million cases and 608,000 deaths in 2022 worldwide. For pregnant women, particularly those in their first trimester, it can cause serious complications, a concern for over 120 million women
Malaria is one of the most serious infectious diseases affecting predominantly low- and middle-income countries, where pregnant women are among the populations at risk. There are limited options to prevent or treat malaria in pregnancy, particularly in the first trimester,
